Sun Pharmaceutical Industries' shares surged more than 9% following the announcement of its $11.75 billion acquisition of US-based Organon & Co. The deal targets bolstering the Indian company's innovative medicines and positioning it strongly in biosimilars and women's health markets. Organon is recognized as a global leader in women's health.
Sun Pharmaceutical Industries, an Indian pharmaceutical giant, announced the acquisition of Organon & Co., a US company specializing in women's health products, for $11.75 billion. The move, as detailed in reports from The Economic Times, prompted an immediate market reaction with Sun Pharma's shares jumping over 9% on the Bombay Stock Exchange. This transaction aims to enhance Sun Pharma's portfolio in innovative medicines and establish leadership in biosimilars and women's health globally. Sun Pharma, known for its extensive generic drug offerings, sees the deal as a strategic expansion into high-growth areas. Organon, previously part of MSD, brings established expertise and a strong presence in women's health therapeutics. Company officials highlighted the acquisition's potential to drive long-term growth amid increasing global demand for specialized treatments. The announcement underscores a trend among Indian pharma firms pursuing overseas acquisitions to diversify and innovate. Shares of peers like Divi's Laboratories and Dr. Reddy's Laboratories were also monitored closely by investors following the news.
